Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2eu) Breast Cancer: Review

摘要

Tripple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER-2 Over expression. Expression of ER, PR and HER-2 plays an important role in therapeutic assessment of patients with breast cancer. TNBC is not one disease, but a family of diseases, some of which are highly aggressive with limited treatment options. Triple-negative breast cancers Patients are not benefiting from currently available receptor-targeted systemic therapy. At present, there is no single agent that targets triple-negative breast cancer. However, researchers are presently investigating large number of potential therapies that may eventually improve outcomes in these patients. In this review article, we discussed about tripple negative breast cancer, also the role of BRCA gene mutations and targeted therapeutic options available to triple negative breast cancer patients.doi: http://dx.doi.org/10.4021/wjon681e